Cargando…
Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction
Left ventricular (LV) dysfunction after acute myocardial infarction (AMI) is associated with an increased risk of heart failure (HF) development. Diverse microRNAs (miRNAs) have been shown to appear in the bloodstream following various cardiovascular events. The aim of this study was to identify pro...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026144/ https://www.ncbi.nlm.nih.gov/pubmed/29959359 http://dx.doi.org/10.1038/s41598-018-28118-1 |
_version_ | 1783336393637888000 |
---|---|
author | Maciejak, Agata Kostarska-Srokosz, Edyta Gierlak, Wlodzimierz Dluzniewski, Miroslaw Kuch, Marek Marchel, Michal Opolski, Grzegorz Kiliszek, Marek Matlak, Krzysztof Dobrzycki, Slawomir Lukasik, Anna Segiet, Agnieszka Sygitowicz, Grazyna Sitkiewicz, Dariusz Gora, Monika Burzynska, Beata |
author_facet | Maciejak, Agata Kostarska-Srokosz, Edyta Gierlak, Wlodzimierz Dluzniewski, Miroslaw Kuch, Marek Marchel, Michal Opolski, Grzegorz Kiliszek, Marek Matlak, Krzysztof Dobrzycki, Slawomir Lukasik, Anna Segiet, Agnieszka Sygitowicz, Grazyna Sitkiewicz, Dariusz Gora, Monika Burzynska, Beata |
author_sort | Maciejak, Agata |
collection | PubMed |
description | Left ventricular (LV) dysfunction after acute myocardial infarction (AMI) is associated with an increased risk of heart failure (HF) development. Diverse microRNAs (miRNAs) have been shown to appear in the bloodstream following various cardiovascular events. The aim of this study was to identify prognostic miRNAs associated with LV dysfunction following AMI. Patients were divided into subgroups comprising patients who developed or not LV dysfunction within six months of the infarction. miRNA profiles were determined in plasma and serum samples of the patients on the first day of AMI. Levels of 14 plasma miRNAs and 16 serum miRNAs were significantly different in samples from AMI patients who later developed LV dysfunction compared to those who did not. Two miRNAs were up-regulated in both types of material. Validation in an independent group of patients, using droplet digital PCR (ddPCR) confirmed that miR-30a-5p was significantly elevated on admission in those patients who developed LV dysfunction and HF symptoms six months after AMI. A bioinformatics analysis indicated that miR-30a-5p may regulate genes involved in cardiovascular pathogenesis. This study demonstrates, for the first time, a prognostic value of circulating miR-30a-5p and its association with LV dysfunction and symptoms of HF after AMI. |
format | Online Article Text |
id | pubmed-6026144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60261442018-07-09 Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction Maciejak, Agata Kostarska-Srokosz, Edyta Gierlak, Wlodzimierz Dluzniewski, Miroslaw Kuch, Marek Marchel, Michal Opolski, Grzegorz Kiliszek, Marek Matlak, Krzysztof Dobrzycki, Slawomir Lukasik, Anna Segiet, Agnieszka Sygitowicz, Grazyna Sitkiewicz, Dariusz Gora, Monika Burzynska, Beata Sci Rep Article Left ventricular (LV) dysfunction after acute myocardial infarction (AMI) is associated with an increased risk of heart failure (HF) development. Diverse microRNAs (miRNAs) have been shown to appear in the bloodstream following various cardiovascular events. The aim of this study was to identify prognostic miRNAs associated with LV dysfunction following AMI. Patients were divided into subgroups comprising patients who developed or not LV dysfunction within six months of the infarction. miRNA profiles were determined in plasma and serum samples of the patients on the first day of AMI. Levels of 14 plasma miRNAs and 16 serum miRNAs were significantly different in samples from AMI patients who later developed LV dysfunction compared to those who did not. Two miRNAs were up-regulated in both types of material. Validation in an independent group of patients, using droplet digital PCR (ddPCR) confirmed that miR-30a-5p was significantly elevated on admission in those patients who developed LV dysfunction and HF symptoms six months after AMI. A bioinformatics analysis indicated that miR-30a-5p may regulate genes involved in cardiovascular pathogenesis. This study demonstrates, for the first time, a prognostic value of circulating miR-30a-5p and its association with LV dysfunction and symptoms of HF after AMI. Nature Publishing Group UK 2018-06-29 /pmc/articles/PMC6026144/ /pubmed/29959359 http://dx.doi.org/10.1038/s41598-018-28118-1 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Maciejak, Agata Kostarska-Srokosz, Edyta Gierlak, Wlodzimierz Dluzniewski, Miroslaw Kuch, Marek Marchel, Michal Opolski, Grzegorz Kiliszek, Marek Matlak, Krzysztof Dobrzycki, Slawomir Lukasik, Anna Segiet, Agnieszka Sygitowicz, Grazyna Sitkiewicz, Dariusz Gora, Monika Burzynska, Beata Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction |
title | Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction |
title_full | Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction |
title_fullStr | Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction |
title_full_unstemmed | Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction |
title_short | Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction |
title_sort | circulating mir-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026144/ https://www.ncbi.nlm.nih.gov/pubmed/29959359 http://dx.doi.org/10.1038/s41598-018-28118-1 |
work_keys_str_mv | AT maciejakagata circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT kostarskasrokoszedyta circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT gierlakwlodzimierz circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT dluzniewskimiroslaw circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT kuchmarek circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT marchelmichal circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT opolskigrzegorz circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT kiliszekmarek circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT matlakkrzysztof circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT dobrzyckislawomir circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT lukasikanna circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT segietagnieszka circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT sygitowiczgrazyna circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT sitkiewiczdariusz circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT goramonika circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction AT burzynskabeata circulatingmir30a5pasaprognosticbiomarkerofleftventriculardysfunctionafteracutemyocardialinfarction |